美国FORTA列表:改善老年人药物治疗的临床工具共识验证
美国基于两步Delphi法,以欧洲FORTA列表为模板,由8名美国老年医学专家对药物适宜性进行评级,形成包含273个条目、27个主要适应症组的美国FORTA列表;其中新增30种药物/药物组,移除23种美国不可及药物;与欧洲列表相比,痴呆相关睡眠障碍的标签变更比例最高(40%);绝大多数条目(95.5%)被接受。
要点
- 美国FORTA列表含273个条目,覆盖27个主要适应症组。
- 新增30种药物/药物组,移除23种美国不可及药物。
- 与欧洲列表相比,痴呆相关睡眠障碍标签变更比例最高(40%)。
核心结论
- 美国FORTA列表反映美国药物可及性、使用习惯和专家评级,用于评估老年人药物适宜性。
研究设计与样本
- 采用两步Delphi法,以欧洲FORTA列表为模板,由8名美国老年医学专家/药师作为评级者对列表条目进行增删或重新标记。
主要发现
- 第一版美国FORTA列表包含273个条目,对应27个主要适应症组。
- 新增30种药物和药物组,移除23种美国不可及的药物。
- 与欧洲FORTA列表相比,痴呆相关睡眠障碍的FORTA标签变更比例最高(40%)。
- 在8个适应症中,11个条目的标签与提案不同。
- 多数条目(n=232,95.5%)的提案被美国评级者接受;仅16个条目(6.6%,n=243)因第一轮评级不一致需第二轮重新评估。
关键数值与推荐
- FORTA分类标签为A(绝对适用)、B(有益)、C(谨慎)、D(不适用)。
- 美国FORTA列表含273个条目,覆盖27个主要适应症组。
- 新增30种药物/药物组,移除23种美国不可及药物。
- 痴呆相关睡眠障碍的标签变更比例最高(40%)。
- 95.5%(n=232)的提案条目被接受,6.6%(16/243)需第二轮重新评估。
临床怎么用
- 临床医生可参考美国FORTA列表对老年人药物进行A/B/C/D适宜性评级,以优化多重用药和共病管理。
局限性
- 原文未报告列表在临床结局上的验证数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Polypharmacy and multimorbidity is a threat to older people; hence, listing approaches should support physicians to optimize medication. The FORTA (Fit fOR The Aged) classification of drug appropriateness for older people provides positive or negative labels: A (A-bsolutely), B (B-eneficial), C (C-areful), and D (D-on't). Based on these categories, FORTA-labeled drug lists were developed in 7 European countries or regions; the same approach was used to develop a U.S.-FORTA List reflecting the country-specific availability and usage of drugs. DESIGN/SETTING: A 2-step Delphi-type approach was employed to add, remove, or relabel drugs from the listing proposal and to add or remove new indications. The proposal utilized the European (EURO)-FORTA list as template. PARTICIPANTS: Eight US-based geriatricians/pharmacists served as raters. MEASUREMENTS: Raters gave recommendations and comments on the list items. RESULTS: The first U.S.-FORTA List contains 273 items aligned to 27 main indication groups; 30 drugs and drug groups were added, and 23 removed as being unavailable in the United States. The highest percentage of changes in FORTA labels as compared to the EURO-FORTA List occurred for sleep disorders associated with dementia (40%). In 8 indications, the labels for 11 items were different from the proposal. Thus, for the majority of the items (n = 232, 95.5%), the proposals were accepted by the US raters. Only 16 (6.6%) of the proposed items (n = 243) had to be re-evaluated in the second round as a result of inconsistent rating in the first round. CONCLUSIONS AND IMPLICATIONS: The U.S.-FORTA List addresses the appropriateness of drugs for older people in the United States reflecting country-specific availability, usage, and expert rating. As shown for the FORTA list in Europe, this listing approach is among the few that are clinically validated and improve well-being and geriatric outcomes. The U.S.-FORTA List now largely enhances the global availability of this approach.
引用
- Pazan F, Gercke Y, Weiss C, et al. The U.S.-FORTA (Fit fOR The Aged) List: Consensus Validation of a Clinical Tool to Improve Drug Therapy in Older Adults. J Am Med Dir Assoc. 2019. PMID: 31542300. doi:10.1016/j.jamda.2019.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。